Mecbotamab vedotin

N/A

Report date: 2024/02/05 13:52:45

Base Information

Drug NameMecbotamab vedotin
Drug Alias NameCAB-Axl antibody-drug conjugates - BioAtlaBA-3011 - BioAtlaCAB-AXL-ADC - BioAtlaBA-3011BA3011 +[6] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker > VC linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > MMAE payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionAXL receptor tyrosine kinase inhibitorsTubulin inhibitors
TargetsAXL receptor tyrosine kinaseTubulin
Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungOvarian NeoplasmsSarcoma +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesTaiwan +[9] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesBioAtla Inc
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesBristol-Myers Squibb CompanyKaibosi (Shanghai) Biomedical Co LtdBioAtla Inc
Inactive CompaniesN/A
Active IndicationsCarcinoma, Non-Small-Cell LungOvarian NeoplasmsSarcoma +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A